Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 30;94(43):e1898. doi: 10.1097/MD.0000000000001898

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.

This is an open access article distributed under the Creative Commons Attribution-NonCommercial License, where it is permissible to download, share and reproduce the work in any medium, provided it is properly cited. The work cannot be used commercially. http://creativecommons.org/licenses/by-nc/4.0

PMC Copyright notice

Intravenous immunoglobulin (IVIg) was more effective in treating mechanically ventilated Guillain–Barré syndrome (GBS) patients. The clinical severity revealed by Medical Research Council (MRC) at nadir of the mechanically ventilated GBS patients in the IVIg treatment groups was 16.8 while it was 16.3 in the combination therapy group (P > 0.05), indicating the comparable muscle weakness between the 2 groups (A). Moreover, more patients were found improvement after IVIg treatment as assessed by the improvement of MRC sum score (97%) and Hughes Functional Grading Scale (HFGS) score (97%) compared with that in the combination therapy group (MRC: 72.4%; HFGS: 72.4%) (B).